БИНЧ Хэйли (US),МОРТИМОР Майкл (GB),ФРАЙСС Дамьен (GB),РЕЗЕРФОРД Элистер (GB)
申请号：
RU2011118227/15
公开号：
RU2011118227A
申请日:
2011.05.05
申请国别(地区):
RU
年份:
2012
代理人:
摘要：
1. A method of treating cancer in a patient in need of treatment, comprising sequentially or co-administering a compound of formula I or a pharmaceutically acceptable salt thereof and another therapeutic agent:! ! or its tautomer, or a pharmaceutically acceptable salt thereof, where! R2 is C1-3 alkyl or cyclopropyl； ! R9 is halogen, C1-3-alkyl, -O- (C1-3-alkyl), -S- (C1-3-alkyl) or CF3 and! p is 1-2. ! 2. The method according to claim 1, where the specified therapeutic agent is selected from taxanes, bcr-abl inhibitors, EGFR inhibitors, DNA damaging agents and antimetabolites. ! 3. The method according to claim 1 or 2, where the specified therapeutic agent is selected from paclitaxel, glivec, dasatinib, nilotinib, tarseva, iressa, cisplatin, oxaliplatin, carboplatin, anthracyclines, AraC and 5-FU. ! 4. The method according to claim 1 or 2, wherein said therapeutic agent is selected from camptothecin, doxorubicin, idarubicin, cisplatin, taxol, taxotere, vincristine, tarseva, MEK inhibitor, U0126, KSP inhibitor, vorinostat, glivec, dasatinib and nilotinib. ! 5. A method of treating cancer in a patient in need of treatment, comprising sequentially or co-administering one or more of the following compounds or their pharmaceutically acceptable salts and another therapeutic agent:! ! 6. The method according to claim 5, where the specified therapeutic agent is selected from taxanes, bcr-abl inhibitors, EGFR inhibitors, DNA damaging agents and antimetabolites. ! 7. The method according to claim 5 or 6, where the specified therapeutic agent is selected from paclitaxel, glivec, dasatinib, nilotinib, tarseva, iressa, cisplatin, oxaliplatin, carboplatin, anthracyclines, AraC and 5-FU. ! 8. The method according to claim 5 or 6, where the specified therapeutic agent1. Способ лечения рака у пациента, нуждающегося в лечении, включающий последовательное или совместное введение соединения формулы I или его фармацевтически приемлемой соли и другого терапевтического агента: ! ! ил
